In addition, in myeloproliferative neoplasms, the loss of PTCH2, and, consequently, Shh pathway activation, it was shown to improve tumor resistance to Fluorouracil (5-FU) treatment [35]. The gene discussed is SHH; the disease is myeloproliferative neoplasm.